Skip to main content
SpringerLink
Log in

Adverse Effects of Cancer Treatment on Hearing

  • Chapter
Survivors of Childhood and Adolescent Cancer

Part of the book series: Pediatric Oncology ((PEDIATRICO))

Abstract

Childhood cancer survivors treated with ototoxic agents require careful evaluation and intervention to mitigate the effects of hearing loss, which has the potential to adversely affect social, emotional, and cognitive functioning. This chapter reviews the pathophysiology, risk factors, and prevalence of hearing loss arising as a consequence of ototoxic agents commonly employed to treat childhood cancer. Clinical manifestations of hearing loss associated with tumor, surgery, radiation, and pharmacologic agents are discussed. Screening and diagnostic audiometry are described, and guidelines for audiologic monitoring and grading of ototoxicity are elucidated. Finally, management of hearing loss through the use of hearing aids, cochlear implants, and other assistive devices are examined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Speech-Language-Hearing Association (1994) Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36(Suppl 12):11–19

    Google Scholar 

  2. Bates DE (2003) Aminoglycoside ototoxicity. Drugs Today (Barc) 39:277–285

    Article  CAS  Google Scholar 

  3. Bates DE, Beaumont SJ, Baylis BW (2002) Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother 36:446–451

    Article  PubMed  Google Scholar 

  4. Bertolini P, Lassalle M, Mercier G et al (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649–655

    Article  PubMed  Google Scholar 

  5. Brock PR, Bellman SC, Yeomans EC et al (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300

    Article  CAS  PubMed  Google Scholar 

  6. Brock PR, Knight KR, Freyer DR et al (2012) Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 30:2408–2417

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Brookhouser PE (2000) Diseases of the cochlea and labyrinth. In: Wetmore RF, Muntz HR, McGill TJ (eds) Pediatric otolaryngology: principles and practice pathways. Thieme, New York, pp 327–354

    Google Scholar 

  8. Brookhouser PE, Beauchaine KL, Osberger MJ (1999) Management of the child with sensorineural hearing loss. Medical, surgical, hearing aids, cochlear implants. Pediatr Clin North Am 46:121–141

    Article  CAS  PubMed  Google Scholar 

  9. Campbell KC, Durrant J (1993) Audiologic monitoring for ototoxicity. Otolaryngol Clin North Am 26:903–914

    CAS  PubMed  Google Scholar 

  10. Campbell KC, Meech RP, Klemens JJ et al (2007) Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res 226:92–103

    Article  CAS  PubMed  Google Scholar 

  11. Chang KW (2011) Clinically accurate assessment and grading of ototoxicity. Laryngoscope 121:2649–2657

    Article  PubMed  Google Scholar 

  12. Chang KW, Chinosornvatana N (2010) Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788–1795

    Article  CAS  PubMed  Google Scholar 

  13. Cherow E, Dickman DM, Epstein S (1999) Organization resources for families of children with deafness or hearing loss. Pediatr Clin North Am 46:153–162

    Article  CAS  PubMed  Google Scholar 

  14. Children’s Oncology Group (2008) Children’s Oncology Group long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Children’s Oncology Group, Arcadia

    Google Scholar 

  15. Dean JB, Hayashi SS, Albert CM et al (2008) Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 30:130–134

    Article  CAS  PubMed  Google Scholar 

  16. Ding D, Allman BL, Salvi R (2012) Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken) 295:1851–1867

    Article  CAS  Google Scholar 

  17. Doolittle ND, Muldoon LL, Brummett RE et al (2001) Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493–500

    CAS  PubMed  Google Scholar 

  18. Durrant JD, Campbell K, Fausti S et al (2009) American Academy of Audiology position statement and clinical practice guidelines: ototoxicity monitoring. American Academy of Audiology, Reston

    Google Scholar 

  19. Fee WE Jr (1980) Aminoglycoside ototoxicity in the human. Laryngoscope 90:1–19

    Article  PubMed  Google Scholar 

  20. Fouladi M, Chintagumpala M, Ashley D et al (2008) Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26:3749–3755

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Freyer DR, Sung L, Reaman GH (2009) Prevention of hearing loss in children receiving cisplatin chemotherapy. J Clin Oncol 27:317–318, author reply 318–319

    Article  PubMed  Google Scholar 

  22. Gallegos-Castorena S, Martinez-Avalos A, Mohar-Betancourt A et al (2007) Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 24:403–408

    Article  CAS  PubMed  Google Scholar 

  23. Gamble JE, Peterson EA, Chandler JR (1968) Radiation effects on the inner ear. Arch Otolaryngol 88:156–161

    Article  CAS  PubMed  Google Scholar 

  24. Gratton MA, Salvi RJ, Kamen BA et al (1990) Interaction of cisplatin and noise on the peripheral auditory system. Hear Res 50:211–223

    Article  CAS  PubMed  Google Scholar 

  25. Grewal S, Merchant T, Reymond R et al (2010) Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Pediatrics 125:e938–e950

    Article  PubMed Central  PubMed  Google Scholar 

  26. Guillaume DJ, Knight K, Marquez C et al (2012) Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma. J Neurosurg Pediatr 9:421–427

    Article  PubMed  Google Scholar 

  27. Hale GA, Marina NM, Jones-Wallace D et al (1999) Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 21:115–122

    Article  CAS  PubMed  Google Scholar 

  28. Hall JW (2000) Handbook of otoacoustic emissions. Singular, San Diego

    Google Scholar 

  29. Helt-Cameron J, Allen PJ (2009) Cisplatin ototoxicity in children: implications for primary care providers. Pediatr Nurs 35:121–127

    PubMed  Google Scholar 

  30. Hill GW, Morest DK, Parham K (2008) Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol 29:1005–1011

    Article  PubMed Central  PubMed  Google Scholar 

  31. Hua C, Bass JK, Khan R et al (2008) Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys 72:892–899

    Article  PubMed  Google Scholar 

  32. Huang E, Teh BS, Strother DR et al (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52:599–605

    Article  PubMed  Google Scholar 

  33. Ilveskoski I, Saarinen UM, Wiklund T et al (1996) Ototoxicity in children with malignant brain tumors treated with the “8 in 1” chemotherapy protocol. Med Pediatr Oncol 27:26–31

    Article  CAS  PubMed  Google Scholar 

  34. Jehanne M, Lumbroso-Le Rouic L, Savignoni A et al (2009) Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 52:637–643

    Article  PubMed  Google Scholar 

  35. Katzenstein HM, Chang KW, Krailo M et al (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115:5828–5835

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Kemp G, Rose P, Lurain J et al (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112

    CAS  PubMed  Google Scholar 

  37. Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596

    Article  PubMed  Google Scholar 

  38. Knight KR, Kraemer DF, Winter C et al (2007) Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25:1190–1195

    Article  CAS  PubMed  Google Scholar 

  39. Kolinsky DC, Hayashi SS, Karzon R et al (2010) Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol 32:119–123

    Article  CAS  PubMed  Google Scholar 

  40. Kretschmar CS, Warren MP, Lavally BL et al (1990) Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol 8:1191–1198

    CAS  PubMed  Google Scholar 

  41. Kulkarni K, Hartley DE (2008) Recent advances in hearing restoration. J R Soc Med 101:116–124

    Article  PubMed Central  PubMed  Google Scholar 

  42. Kushner BH, Budnick A, Kramer K et al (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417–422

    Article  CAS  PubMed  Google Scholar 

  43. Lambert MP, Shields C, Meadows AT (2008) A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 50:223–226

    Article  PubMed  Google Scholar 

  44. Laverdiere C, Cheung NK, Kushner BH et al (2005) Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 45:324–332

    Article  PubMed  Google Scholar 

  45. Lerner SA, Schmitt BA, Seligsohn R et al (1986) Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 80:98–104

    Article  CAS  PubMed  Google Scholar 

  46. Lewis MJ, DuBois SG, Fligor B et al (2009) Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52:387–391

    Article  PubMed  Google Scholar 

  47. Li Y, Womer RB, Silber JH (2004) Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 40:2445–2451

    Article  CAS  PubMed  Google Scholar 

  48. Low WK, Fong KW (1998) Long-term post-irradiation middle ear effusion in nasopharyngeal carcinoma. Auris Nasus Larynx 25:319–321

    Article  CAS  PubMed  Google Scholar 

  49. Lynch ED, Gu R, Pierce C et al (2005) Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs 16:569–579

    Article  CAS  PubMed  Google Scholar 

  50. Macdonald MR, Harrison RV, Wake M et al (1994) Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 23:151–159

    CAS  PubMed  Google Scholar 

  51. Mann ZF, Kelley MW (2011) Development of tonotopy in the auditory periphery. Hear Res 276:2–15

    Article  PubMed  Google Scholar 

  52. Marina N, Chang KW, Malogolowkin M et al (2005) Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children’s Oncology Group study. Cancer 104(4):841–847

    Google Scholar 

  53. Matz GJ (1993) Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 26:705–712

    CAS  PubMed  Google Scholar 

  54. Merchant TE, Gould CJ, Xiong X et al (2004) Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys 58:1194–1207

    Article  PubMed  Google Scholar 

  55. Meyer WH, Ayers D, McHaney VA et al (1993) Ifosfamide and exacerbation of cisplatin-induced hearing loss. Lancet 341:754–755

    Article  CAS  PubMed  Google Scholar 

  56. Moeller BJ, Chintagumpala M, Philip JJ et al (2011) Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol 6:58

    Article  PubMed Central  PubMed  Google Scholar 

  57. Mukherjea D, Rybak LP (2011) Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 12:1039–1050

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Musial-Bright L, Fengler R, Henze G et al (2011) Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 27:407–413

    Article  PubMed  Google Scholar 

  59. National Cancer Institute (2006) Common terminology criteria for adverse events, version 3.0, http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

  60. National Cancer Institute (2010) Common terminology criteria for adverse events, version 4.0, http://evs.nci.nih.gov/ftp1/CTCAE/About.html

  61. Neuwelt EA, Brock P (2010) Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28:1630–1632

    Article  PubMed  Google Scholar 

  62. Neuwelt EA, Pagel MA, Kraemer DF et al (2004) Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309:594–599

    Article  CAS  PubMed  Google Scholar 

  63. Neuwelt EA, Brummett RE, Doolittle ND et al (1998) First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 286:77–84

    CAS  PubMed  Google Scholar 

  64. Oldenburg J, Kraggerud SM, Cvancarova M et al (2007) Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708–714

    Article  CAS  PubMed  Google Scholar 

  65. Orgel E, Jain S, Ji L et al (2012) Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer 58:953–958

    Article  PubMed  Google Scholar 

  66. Papsin BC, Gordon KA (2007) Cochlear implants for children with severe-to-profound hearing loss. N Engl J Med 357:2380–2387

    Article  CAS  PubMed  Google Scholar 

  67. Parsons SK, Neault MW, Lehmann LE et al (1998) Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669–674

    Article  CAS  PubMed  Google Scholar 

  68. Pecora Liberman PH, Schultz C, Schmidt Goffi-Gomez MV et al (2011) Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation. Clin Transl Oncol 13:348–352

    Article  PubMed  Google Scholar 

  69. Peters U, Preisler-Adams S, Hebeisen A et al (2000) Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11:639–643

    Article  CAS  PubMed  Google Scholar 

  70. Petrilli AS, Oliveira DT, Ginani VC et al (2002) Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol 24:188–191

    Article  PubMed  Google Scholar 

  71. Portnuff CD, Fligor BJ, Arehart KH (2011) Teenage use of portable listening devices: a hazard to hearing? J Am Acad Audiol 22:663–677

    Article  PubMed  Google Scholar 

  72. Qaddoumi I, Bass JK, Wu J et al (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30:1034–1041

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Reddel RR, Kefford RF, Grant JM et al (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66:19–23

    CAS  PubMed  Google Scholar 

  74. Rednam S, Scheurer ME, Adesina A et al (2013) Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer. 60:593–598

    Google Scholar 

  75. Riedemann L, Lanvers C, Deuster D et al (2008) Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8:23–28

    Article  CAS  PubMed  Google Scholar 

  76. Riggs LC, Brummett RE, Guitjens SK et al (1996) Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope 106:401–406

    Article  CAS  PubMed  Google Scholar 

  77. Roland JT, Cohen NL et al (1998) Vestibular and auditory ototoxicity. In: Cummings CW, Fredrickson JM, Harker LA (eds) Otolaryngology head and neck surgery, 3rd edn. Mosby, St. Louis, pp 3186–3197

    Google Scholar 

  78. Ross CJ, Katzov-Eckert H, Dube MP et al (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41:1345–1349

    Article  CAS  PubMed  Google Scholar 

  79. Rybak LP (1993) Ototoxicity of loop diuretics. Otolaryngol Clin North Am 26:829–844

    CAS  PubMed  Google Scholar 

  80. Rybak LP, Whitworth CA, Mukherjea D et al (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226:157–167

    Article  CAS  PubMed  Google Scholar 

  81. Schacht J, Talaska AE, Rybak LP (2012) Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken) 295:1837–1850

    Article  CAS  Google Scholar 

  82. Schell MJ, McHaney VA, Green AA et al (1989) Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7:754–760

    CAS  PubMed  Google Scholar 

  83. Schweitzer VG (1993) Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 26:759–789

    CAS  PubMed  Google Scholar 

  84. Simon MV (2011) Neurophysiologic intraoperative monitoring of the vestibulocochlear nerve. J Clin Neurophysiol 28:566–581

    Article  PubMed  Google Scholar 

  85. Simon T, Hero B, Dupuis W et al (2002) The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 214:149–152

    Article  CAS  PubMed  Google Scholar 

  86. Sininger YS, Doyle KJ, Moore JK (1999) The case for early identification of hearing loss in children. Auditory system development, experimental auditory deprivation, and development of speech perception and hearing. Pediatr Clin North Am 46:1–14

    Article  CAS  PubMed  Google Scholar 

  87. Smith CR, Lipsky JJ, Laskin OL et al (1980) Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302:1106–1109

    Article  CAS  PubMed  Google Scholar 

  88. Stach BA (1998) Clinical audiology: an introduction. Singular, San Diego

    Google Scholar 

  89. Stohr W, Langer T, Kremers A et al (2004) Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the late effects surveillance system. Oncol Rep 12:767–771

    CAS  PubMed  Google Scholar 

  90. Stringer SP, Meyerhoff WL, Wright CG (1991) Ototoxicity. In: Paparella MM, Shumrick DA (eds) Otolaryngology, 3rd edn. Saunders, Philadelphia, pp 1653–1669

    Google Scholar 

  91. Sullivan MJ (2009) Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears. Cancer 115:5623–5626

    Article  CAS  PubMed  Google Scholar 

  92. Takeno S, Harrison RV, Ibrahim D et al (1994) Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res 75:93–102

    Article  CAS  PubMed  Google Scholar 

  93. Thomas Dickey D, Muldoon LL, Kraemer DF et al (2004) Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193:25–30

    Article  CAS  PubMed  Google Scholar 

  94. Turner CW (2006) Hearing loss and the limits of amplification. Audiol Neurootol 11(Suppl 1):2–5

    Article  PubMed  Google Scholar 

  95. Walker GV, Ahmed S, Allen P et al (2011) Radiation-induced middle ear and mastoid opacification in skull base tumors treated with radiotherapy. Int J Radiat Oncol Biol Phys 81:e819–e823

    Article  PubMed  Google Scholar 

  96. Weatherly RA, Owens JJ, Catlin FI et al (1991) cis-platinum ototoxicity in children. Laryngoscope 101:917–924

    Article  CAS  PubMed  Google Scholar 

  97. Whelan K, Stratton K, Kawashima T et al (2011) Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer 57:126–134

    Article  PubMed Central  PubMed  Google Scholar 

  98. Wimmer C, Mees K, Stumpf P et al (2004) Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 25:33–40

    Article  PubMed  Google Scholar 

  99. Yildirim M, Inancli HM, Samanci B et al (2010) Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate. Kulak Burun Bogaz Ihtis Derg 20:173–183

    PubMed  Google Scholar 

  100. Young YH, Lu YC (2001) Mechanism of hearing loss in irradiated ears: a long-term longitudinal study. Ann Otol Rhinol Laryngol 110:904–906

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Hematology/Oncology, Institute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

    Wendy Landier PhD, CRNP

  2. LIFE Cancer Survivorship and Transition Program, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA

    David R. Freyer DO, MS

  3. Department of Clinical Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    David R. Freyer DO, MS

Authors
  1. Wendy Landier PhD, CRNP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David R. Freyer DO, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy Landier PhD, CRNP .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, MD Anderson Cancer Center, Houston, Texas, USA

    Cindy L. Schwartz

  2. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Wendy L. Hobbie

  3. Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, James P. Wilmot Cancer Ctr, Rochester, New York, USA

    Louis S. Constine

  4. Center for Cancer And Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA

    Kathleen S. Ruccione

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Landier, W., Freyer, D.R. (2015). Adverse Effects of Cancer Treatment on Hearing. In: Schwartz, C., Hobbie, W., Constine, L., Ruccione, K. (eds) Survivors of Childhood and Adolescent Cancer. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-16435-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16435-9_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16434-2

  • Online ISBN: 978-3-319-16435-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation